A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)

NCT00797745 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

BIOLOGICAL: peginterferon alfa 2b
DRUG: ribavirin
DRUG: SCH 900518
DRUG: ritonavir

Sponsor

Merck Sharp & Dohme LLC